



# GENITOURINARY TUMORS CONCLAVE 2022

BEYOND THE GUIDELINES:  
CLINICAL PERSPECTIVES  
ON THE MANAGEMENT OF  
GENITOURINARY TUMORS

SAVE THE DATE

8<sup>th</sup> – 9<sup>th</sup> July, 2022

6:30 – 9:10 pm

## Program Directors



### Dr. Hemant Malhotra

Director, Oncology Services,  
Sri Ram Cancer & Super Speciality Center &  
Prof. & Head, Dept. of Medical Oncology,  
Mahatma Gandhi Medical College Hospital,  
Jaipur



### Dr. Sadashivudu Gundeti

Additional Professor & HOD,  
Nizam's Institute of Medical Sciences,  
Hyderabad

[Click here for disclaimer](#)

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory



Pfizer Products India Private Limited ("Pfizer") The Capital, B wing, 1802, Plot No. C-70, G Block,  
Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India

This email message is intended for registered Healthcare Practitioner (HCP)

Disclaimer- Kindly note that the article provided is procured only for the use of the requestor, to keep them updated on recent medical developments and advances. This article is for your personal reference. Per copyright policy, it is not to be further reproduced or disseminated.  
Legal Notice - Unless expressly stated otherwise, this message is confidential and may be privileged. It is intended for the addressee[s] only. Access to this e-mail by anyone else is unauthorized. If you are not an addressee, any disclosure or copying of the contents of this e-mail or any action taken [or not taken] in reliance on it is unauthorized and may be unlawful. If you are not an addressee, please inform the sender immediately



# GENITOURINARY TUMORS CONCLAVE 2022

BEYOND THE GUIDELINES:  
CLINICAL PERSPECTIVES ON  
THE MANAGEMENT  
OF GENITOURINARY TUMORS

8<sup>th</sup> – 9<sup>th</sup> July, 2022

8<sup>th</sup> July 2022 | 6:30–9:10 pm

Day 1

## Scientific Program

6:30 – 6:40 pm	Welcome and Introduction <b>Program Director &amp; Pfizer Medical</b>
6:40 – 7:00 pm	Current Treatment landscape for first line therapy for urothelial carcinoma <b>Speaker : Dr. Meenu Walia</b>
7:00 – 7:30 pm	Challenges in selecting first-line therapy for urothelial carcinoma – <ul style="list-style-type: none"><li>• Current first-line therapy guidelines and recommendations</li><li>• Clinical scenarios in which ICI therapy is the optimal treatment course<ul style="list-style-type: none"><li>• Cisplatin-ineligible patients</li><li>• PD-L1 expression and agent specific assays and expression thresholds</li></ul></li></ul> <b>Speaker : Dr. Thomas Powles</b>
7:30 – 7:50 pm	Treatment Refractory advanced urothelial cancer <ul style="list-style-type: none"><li>• Sequencing strategies, considerations, and challenges</li></ul> <b>Speaker : Dr. B J Srinivas</b>
7:50 – 8:10 pm	Key studies in urothelial carcinoma– Conference highlights from ASCO GU 2022 and ASCO <b>Speaker : Dr. Chirag Desai</b>

[Click here for disclaimer](#)




Pfizer Products India Private Limited (“Pfizer”) The Capital, B wing, 1802, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India

This email message is intended for registered Healthcare Practitioner (HCP)

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory

Disclaimer- Kindly note that the article provided is procured only for the use of the requestor, to keep them updated on recent medical developments and advances. This article is for your personal reference. Per copyright policy, it is not to be further reproduced or disseminated.  
Legal Notice - Unless expressly stated otherwise, this message is confidential and may be privileged. It is intended for the addressee[s] only. Access to this e-mail by anyone else is unauthorized. If you are not an addressee, any disclosure or copying of the contents of this e-mail or any action taken [or not taken] in reliance on it is unauthorized and may be unlawful. If you are not an addressee, please inform the sender immediately



# GENITOURINARY TUMORS CONCLAVE 2022

BEYOND THE GUIDELINES:  
CLINICAL PERSPECTIVES ON  
THE MANAGEMENT  
OF GENITOURINARY TUMORS

8<sup>th</sup> – 9<sup>th</sup> July, 2022

8<sup>th</sup> July 2022 | 6:30–9:10 pm

Day 1

## Scientific Program

8:10 – 8:25 pm

Case presentation- An Indian Perspective  
Critical analysis of the case  
**Speaker : Dr. P S Dattatreya**

8:25 – 8:40 pm

Panel Discussion: Considerations related to  
everyday clinical practice  
**Moderator : Dr. Vineet Talwar**  
**Panelists : All speakers**

8:40 – 9:00 pm

**Chairperson : Dr. Rajat Saha**

Debate:  
What is the best strategy for management of  
cisplatin ineligible patients: Gem-carbo  
followed by IO maintenance or IO  
monotherapy  
**For : Dr. Biwas Biswas**  
**Against : Dr. Priya Tiwari**

9:00 – 9:05 pm

Live Q and A

9:05 – 9:10 pm

Closing Remarks  
**Program Director & Pfizer Medical**

[Click here for disclaimer](#)



Pfizer Products India Private Limited ("Pfizer") The Capital, B wing, 1802, Plot No. C-70, G Block,  
Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India

This email message is intended for registered Healthcare Practitioner (HCP)

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory

Disclaimer- Kindly note that the article provided is procured only for the use of the requestor, to keep them updated on recent medical developments and advances. This article is for your personal reference. Per copyright policy, it is not to be further reproduced or disseminated.  
Legal Notice - Unless expressly stated otherwise, this message is confidential and may be privileged. It is intended for the addressee[s] only. Access to this e-mail by anyone else is unauthorized. If you are not an addressee, any disclosure or copying of the contents of this e-mail or any action taken [or not taken] in reliance on it is unauthorized and may be unlawful. If you are not an addressee, please inform the sender immediately





# GENITOURINARY TUMORS CONCLAVE 2022

BEYOND THE GUIDELINES:  
CLINICAL PERSPECTIVES ON  
THE MANAGEMENT  
OF GENITOURINARY TUMORS

8<sup>th</sup> – 9<sup>th</sup> July, 2022

9<sup>th</sup> July 2022 | 6:30–9:10 pm

Day 2

## Scientific Program

6:30 – 6:40 pm	Welcome and Introduction <b>Program Director &amp; Pfizer Medical</b>
6:40 – 7:00 pm	Current Treatment landscape for first line therapy for renal cell carcinoma <b>Speaker : Dr. Mohit Agarwal</b>
7:00 – 7:30 pm	Immuno-Oncology combinations in Advanced RCC: Building on recent progress and improving patient outcomes <b>Speaker : Dr. Enrique Grande</b>
7:30 – 7:50 pm	Treatment Refractory advanced renal cell carcinoma-Second line therapy and beyond <ul style="list-style-type: none"><li>• Sequencing strategies, considerations, and challenges</li></ul> <b>Speaker : Dr. Amit Joshi</b>
7:50 – 8:10 pm	Key studies in metastatic renal carcinoma-Conference highlights from ASCO GU 2022 and ASCO <b>Speaker : Dr. Vindhya Vasini</b>
8:10 – 8:25 pm	Case presentation- An Indian Perspective Critical analysis of the case <b>Speaker : Dr. P N Mohapatra</b>
8:25 – 8:40 pm	Panel Discussion : Considerations related to everyday clinical practice and discussion <b>Moderator : Dr. Prasad Narayanan</b> <b>Panelists : All speakers</b>

[Click here for disclaimer](#)



Pfizer Products India Private Limited ("Pfizer") The Capital, B wing, 1802, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India

This email message is intended for registered Healthcare Practitioner (HCP)

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory

Disclaimer- Kindly note that the article provided is procured only for the use of the requestor, to keep them updated on recent medical developments and advances. This article is for your personal reference. Per copyright policy, it is not to be further reproduced or disseminated.  
Legal Notice - Unless expressly stated otherwise, this message is confidential and may be privileged. It is intended for the addressee[s] only. Access to this e-mail by anyone else is unauthorized. If you are not an addressee, any disclosure or copying of the contents of this e-mail or any action taken [or not taken] in reliance on it is unauthorized and may be unlawful. If you are not an addressee, please inform the sender immediately



# GENITOURINARY TUMORS CONCLAVE 2022

BEYOND THE GUIDELINES:  
CLINICAL PERSPECTIVES ON  
THE MANAGEMENT  
OF GENITOURINARY TUMORS

8<sup>th</sup> – 9<sup>th</sup> July, 2022

9<sup>th</sup> July 2022 | 6:30–9:10 pm

Day 2

## Scientific Program

8:40 – 9:00 pm

**Chairperson : Dr. Kumar Prabhash**

Debate:

Immune Checkpoint Inhibitor Combination  
Therapy versus TKI alone as First-Line  
Treatment for Favorable-IMDC-Risk Advanced  
Renal Cell Carcinoma Patients

**For : Dr. Ashish Singh**

**Against : Dr. Ravi Thippeswamy**

9:00 – 9:05 pm

Live Q and A

9:05 – 9:10 pm

Closing Remarks

**Program Director & Pfizer Medical**

Webinar Management

**riveroute**<sup>®</sup>

Leaders in Streaming Modules

Mobile: +91 9082484474

E-mail : rrcg.pravin@gmail.com

[Click here for disclaimer](#)



Pfizer Products India Private Limited ("Pfizer") The Capital, B wing, 1802, Plot No. C-70, G Block,  
Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India

This email message is intended for registered Healthcare Practitioner (HCP)

Disclaimer- Kindly note that the article provided is procured only for the use of the requestor, to keep them updated on recent medical developments and advances. This article is for your personal reference. Per copyright policy, it is not to be further reproduced or disseminated.  
Legal Notice - Unless expressly stated otherwise, this message is confidential and may be privileged. It is intended for the addressee[s] only. Access to this e-mail by anyone else is unauthorized. If you are not an addressee, any disclosure or copying of the contents of this e-mail or any action taken [or not taken] in reliance on it is unauthorized and may be unlawful. If you are not an addressee, please inform the sender immediately